UNSPSC 51111868: Terguride

This classification denotes a lisuride analog, ergoline, and dopamine agonist with the molecular formula C20H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21OJT43Q88, chemically known as 9,10-alpha-dihydrolisuride but generally known as terguride, which bears US NIH Compound Identifier 37816. European Medicines Agency schedules Terguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10923MIG.

UNSPSC 51111868 Terguride, a Commodity code, covers generic pharmaceutical active ingredients and finished drug products supplied through state and local cooperative purchasing arrangements. State and local government actually buys generic multi-source pharmaceuticals and over-the-counter products under this code, sourced through authorized pharmaceutical wholesalers and distributed to participating state agencies, local government facilities, and health systems. The primary issuing body for recent activity is Minnesota's multistate cooperative purchasing vehicle — the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement — which consolidates demand across participating states including Oregon. Vendors must meet stringent regulatory and operational requirements: current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, FDA approval, contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), electronic data interchange capability, and comprehensive insurance coverage including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability. Products must be available in the marketplace and achievable shelf life of at least six months from manufacture date.

MMCAP's recent RFP (S1070000015802), posted January 20, 2026 with responses due March 26, 2026, seeks manufacturers to supply generic pharmaceuticals with detailed product specifications including National Drug Codes, SKUs, UPCs, and strength/dosage configurations through the ePro procurement system. The evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative fee compliance, EDI capability, and format adherence. Awarded vendors will begin supplying through authorized wholesalers on July 1, 2026, under a two-year contract term with optional MMCAP extensions, and must remit a 3 percent administrative fee on all contract purchases. No specific set-aside designations or budget ranges are disclosed in available solicitation materials, and MMCAP reserves discretion to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.